Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

Neurology

Biomedical/pharma, Neurology

Biogen’s controversial Alzheimer’s drug approved by the FDA – what now?

It has been three months since the much-discussed FDA approval of Biogen’s Aduhelm, a treatment for Alzheimer’s Disease. The drug has been celebrated by some as a breakthrough for Alzheimer’s patients, but others remain highly sceptical or even openly opposed to the FDA decision. What has caused the furor? And what will this approval mean for other biotech companies developing new drugs for neurodegenerative diseases (and for the VCs backing them)?

Newton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy

Augustine Therapeutics developing new medicines for neuromuscular diseases

Augustine Therapeutics had a lot of announcements this month: the VIB spin-off just appointed Dr. Sylvain Celanire as CEO, strengthened its Board of Directors, set up a Scientific Advisory Board and received a €1.2 million VLAIO grant. All of the above is going to help the company to develop therapies for rare peripheral neuropathies and neurodegenerative disorders, starting with Charcot-Marie-Tooth disease. Backed by some major players in the Belgian life sciences ecosystem, this start-up is accelerating fast!

Augustine Therapeutics awarded EUR 1.2 million VLAIO research grant to develop new medicines for neuromuscular diseases

Leuven, Belgium, 23 March 2021 - Augustine Therapeutics, a biotech spin-out company from VIB that focuses on the development of novel innovative therapies for rare peripheral neuropathies and neurodegenerative disorders, has received EUR 1.2 million in funding from the Flanders Agency for Innovation & Entrepreneurship (VLAIO). The grant will be used to support the development of new medicines for peripheral neuropathies through innovative research by elucidating the mode of action of second-generation selective HDAC6 inhibitors developed by Augustine Therapeutics.

Augustine Therapeutics strengthens Board of Directors and sets up Scientific Advisory Board

Leuven, Belgium, 19th March 2021 - Augustine Therapeutics, a biotech company focused on the development of innovative medicines for rare peripheral neuropathies and neurodegenerative diseases, announces the strengthening of the company with seasoned senior executive Dr. Erik Tambuyzer joining the Board of Directors. Tambuyzer brings valuable insights based on his long- lasting work in the biotech industry and with patients’ organizations for rare diseases. Academic researchers Dr. Ludo Van Den Bosch and Dr. Joris de Wit are joining the company’s Scientific Advisory Board. The reinforcement of Augustine Therapeutics’ boards is another important step in strengthening the company to further the development of new medicines treating multiple neurodegenerative diseases with high unmet need.

Augustine Therapeutics appoints Sylvain Celanire as CEO to accelerate development of innovative medicines for rare neuromuscular diseases

Leuven, Belgium, 18th March 2021 - Augustine Therapeutics, a biotech company focused on the development of innovative medicines for rare peripheral neuropathies and neurodegenerative diseases, announces the appointment of Dr. Sylvain Celanire, PhD as its Chief Executive Officer and the opening of drug discovery laboratories at the Leuven Bio-Incubator in Belgium.

Prestigious prize for Belgian breakthrough in brain research

Prof. Dr. Pierre Vanderhaeghen from VIB-KU Leuven has been awarded the Generet Prize for Rare Diseases for his research on human brain development. Vanderhaegen’s team have developed an astonishing model for studying rare neurological disorders by successfully integrating human neurons into a mouse brain. The prestigious prize, managed by the King Baudouin Foundation and presented to Vanderhaeghen by HRH Princess Astrid, includes EUR 1 million in funding for further studies.

Decades-old discoveries cause paradigm shifts in modern medicine

Complete paradigm shifts in medicine are rare, but there have nevertheless been several major examples in the past hundred years. Treatments and approaches that seemed set in stone one decade can easily seem silly the next, as new information about the disease or underlying biology comes to light. Hindsight grants us clarity, but sometimes the factors that lead us down a particular treatment path can be as arbitrary as a feud between colleagues. Might there be paradigm shifts looming in oncology, neurology and more, triggered by a return to previous treatments?

A novel approach to neurology could bring relief to people in pain

In August 2020, V-Bio Ventures announced their investment in Biodol Therapeutics, a French start-up looking to make a difference to people suffering from chronic pain. The company is developing a drug to treat neuropathic pain by addressing the interplay between nerves and the immune system. In a billion-dollar market dominated by ineffective and dangerous painkillers, their unique approach could reduce the suffering of millions.

Biodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures

V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain treatments. Biodol Therapeutics receives EUR 4.5 million to develop novel FLT3 inhibitors for the treatment of chronic and neuropathic pain, aiming to reach the clinic by early 2023.

Augustine Therapeutics: bridging the valley of death with VIB Discovery Sciences

Augustine Therapeutics is one of VIB’s latest spinoffs, developing a first-in-class drug for Charcot-Marie-Tooth disease. The company recently announced a seed-funding round of €4.2 million, led by V-Bio Ventures. We spoke to several of the key persons in Augustine about how the startup is tackling the “Valley of Death”: the no-man’s-land between academia and industry where many potential therapies often fail.

Magic mushrooms in modern medicine

Orphan CNS diseases receive attention with new Minoryx site in Belgium

Microbiome linked to depression in a groundbreaking Benelux study

Rewind Therapeutics secures funding for Multiple Sclerosis research